[{"orgOrder":0,"company":"Sycamore BioPharma","sponsor":"Branded Legacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sycamore BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Sycamore BioPharma \/ Branded Legacy","highestDevelopmentStatusID":"15","companyTruncated":"Sycamore BioPharma \/ Branded Legacy"}]

Find Clinical Drug Pipeline Developments & Deals by Sycamore BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The acquisition expands Branded Legacy's portfolio ranging from gummies to compression sleeves and topical creams, including Relief Gummy, which contains a balanced ratio of CBD to Nano Delta-9-THC.

                          Product Name : Relief Gummy

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Branded Legacy

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank